Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOXIRI-3 for elderly or frail patients with metastatic pancreatic adenocarcinoma
2019-001720-35Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, capecitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by CHU de Besançon. Primary endpoint: 6-month progression-free survival rate. Started Apr 2019; status: completed.
02
Drugs
irinotecancapecitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2019-001720-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001720-35.